# Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

> **NCT02388048** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 19 (actual)

## Conditions studied

- Leukemia, Lymphoblastic, Chronic

## Interventions

- **DRUG:** Ibrutinib + ofatumumab

## Key facts

- **NCT ID:** NCT02388048
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2024-04-03
- **Final completion:** 2024-04-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388048, "Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02388048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*